Shennon Biotechnologies
Shennon Biotechnologies is developing precision T-cell engager immunotherapies for solid tumors.
$12MFunding
ParticipantAV
AV8 Ventures
Activity from announced rounds
Activity in this selectionOct 17, 2026 · Jul 20, 2026
AV8 Ventures is an investment firm with recorded relationships to Think Bioscience and Shennon Biotechnologies.
Recorded funding activity
Think Bioscience develops small-molecule medicines for historically difficult drug targets. Shennon develops precision T-cell engager immunotherapies for solid tumors. The two financing histories connect the firm to different drug-development approaches without establishing a complete sector or portfolio allocation.
Sources
- Rounds participated in
- 1
- Confirmed lead rounds
- 0 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $12M 1 disclosed · full round size, not this investor’s share